These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 29856035

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.
    Laprairie RB, Bagher AM, Rourke JL, Zrein A, Cairns EA, Kelly MEM, Sinal CJ, Kulkarni PM, Thakur GA, Denovan-Wright EM.
    Neuropharmacology; 2019 Jun; 151():1-12. PubMed ID: 30940536
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients.
    Laprairie RB, Warford JR, Hutchings S, Robertson GS, Kelly ME, Denovan-Wright EM.
    J Neuroimmunol; 2014 Feb 15; 267(1-2):61-72. PubMed ID: 24360910
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease.
    Scotter EL, Goodfellow CE, Graham ES, Dragunow M, Glass M.
    Br J Pharmacol; 2010 Jun 15; 160(3):747-61. PubMed ID: 20590577
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias.
    Manning JJ, Green HM, Glass M, Finlay DB.
    Neuropharmacology; 2021 Aug 01; 193():108611. PubMed ID: 34000272
    [Abstract] [Full Text] [Related]

  • 11. Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
    Fernández-Ruiz J, Romero J, Ramos JA.
    Handb Exp Pharmacol; 2015 Aug 01; 231():233-59. PubMed ID: 26408163
    [Abstract] [Full Text] [Related]

  • 12. Antagonism of Dopamine Receptor 2 Long Affects Cannabinoid Receptor 1 Signaling in a Cell Culture Model of Striatal Medium Spiny Projection Neurons.
    Bagher AM, Laprairie RB, Kelly ME, Denovan-Wright EM.
    Mol Pharmacol; 2016 Jun 01; 89(6):652-66. PubMed ID: 27053685
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models.
    Horne EA, Coy J, Swinney K, Fung S, Cherry AE, Marrs WR, Naydenov AV, Lin YH, Sun X, Keene CD, Grouzmann E, Muchowski P, Bates GP, Mackie K, Stella N.
    Eur J Neurosci; 2013 Feb 01; 37(3):429-40. PubMed ID: 23167744
    [Abstract] [Full Text] [Related]

  • 15. Endocannabinoids and Their Pharmacological Actions.
    Pertwee RG.
    Handb Exp Pharmacol; 2015 Feb 01; 231():1-37. PubMed ID: 26408156
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Synthetic and endogenous cannabinoids protect retinal neurons from AMPA excitotoxicity in vivo, via activation of CB1 receptors: Involvement of PI3K/Akt and MEK/ERK signaling pathways.
    Kokona D, Thermos K.
    Exp Eye Res; 2015 Jul 01; 136():45-58. PubMed ID: 25989217
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.